Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) closed the most recent trading day at $771.75, moving -3.45% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Meanwhile, the Dow ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly & Co. LLY shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%.

Assessing Eli Lilly's Performance Against Competitors In Pharmaceuticals Industry November 05, 2024 — 10:00 am EST Written by Benzinga Insights for Benzinga -> ...

Eli Lilly's stock isn't cheap The company's stock trades at a hefty 39 times forward earnings. That's very high for a pharma company and more than twice its main GLP-1 competitor, Novo Nordisk .

However, when looking at the fundamental performance of these two, I don’t see many reasons for the stock outperformance of Eli Lilly. At best, we can call it a head-to-head race.

The stock's fall snapped a four-day winning streak.

During Q3, Eli Lilly brought in $11.4 billion in sales, up 20% from a year prior, and non-GAAP (adjusted) EPS of $1.18, which was $0.29 less than what the average of Wall Street analysts had ...